J&J’s Tremfya Gains First IBD Indication, Setting The Stage For A Big Pharma Showdown

The IL-23 inhibitor was approved by the US FDA for ulcerative colitis, joining AbbVie’s Skyrizi and Lilly’s Omvoh.